Home/Filings/4/0001140361-23-029929
4//SEC Filing

Garren Hideki 4

Accession 0001140361-23-029929

CIK 0001559053other

Filed

Jun 13, 8:00 PM ET

Accepted

Jun 14, 9:15 PM ET

Size

14.1 KB

Accession

0001140361-23-029929

Insider Transaction Report

Form 4
Period: 2023-06-14
Garren Hideki
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Ordinary Shares, par value $0.01 per share

    2023-06-14$24.90/sh+4,669$116,2584,669 total
  • Sale

    Ordinary Shares, par value $0.01 per share

    2023-06-14$72.45/sh509$36,8794,160 total
  • Sale

    Ordinary Shares, par value $0.01 per share

    2023-06-14$73.31/sh971$71,1843,189 total
  • Sale

    Ordinary Shares, par value $0.01 per share

    2023-06-14$74.59/sh2,534$189,010655 total
  • Sale

    Ordinary Shares, par value $0.01 per share

    2023-06-14$75.49/sh655$49,4430 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2023-06-144,669205,331 total
    Exercise: $24.90Exp: 2031-04-05Ordinary Shares (4,669 underlying)
Footnotes (6)
  • [F1]The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023.
  • [F2]The transaction was executed in multiple trades in prices ranging from $71.96 to $72.91, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 5 of this Form 4.
  • [F3]The transaction was executed in multiple trades in prices ranging from $73.03 to $73.995, inclusive.
  • [F4]The transaction was executed in multiple trades in prices ranging from $74.16 to $75.13, inclusive.
  • [F5]The transaction was executed in multiple trades in prices ranging from $75.26 to $76.20, inclusive.
  • [F6]The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on April 5, 2022, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Documents

1 file

Issuer

PROTHENA CORP PUBLIC LTD CO

CIK 0001559053

Entity typeother

Related Parties

1
  • filerCIK 0001854126

Filing Metadata

Form type
4
Filed
Jun 13, 8:00 PM ET
Accepted
Jun 14, 9:15 PM ET
Size
14.1 KB